RU2013110889A - Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки - Google Patents
Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки Download PDFInfo
- Publication number
- RU2013110889A RU2013110889A RU2013110889/10A RU2013110889A RU2013110889A RU 2013110889 A RU2013110889 A RU 2013110889A RU 2013110889/10 A RU2013110889/10 A RU 2013110889/10A RU 2013110889 A RU2013110889 A RU 2013110889A RU 2013110889 A RU2013110889 A RU 2013110889A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- antigens
- antigen
- composition
- virus
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title claims 12
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims 3
- 230000008685 targeting Effects 0.000 title 1
- 239000012646 vaccine adjuvant Substances 0.000 title 1
- 229940124931 vaccine adjuvant Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract 119
- 108091007433 antigens Proteins 0.000 claims abstract 119
- 102000036639 antigens Human genes 0.000 claims abstract 119
- 239000000203 mixture Substances 0.000 claims abstract 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 34
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 30
- 239000000556 agonist Substances 0.000 claims abstract 19
- 241000700605 Viruses Species 0.000 claims abstract 18
- 230000000890 antigenic effect Effects 0.000 claims abstract 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract 13
- 239000012634 fragment Substances 0.000 claims abstract 12
- 230000004048 modification Effects 0.000 claims abstract 11
- 238000012986 modification Methods 0.000 claims abstract 11
- 241000712461 unidentified influenza virus Species 0.000 claims abstract 11
- -1 CD31 Proteins 0.000 claims abstract 9
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract 9
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract 9
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract 9
- 101710176177 Protein A56 Proteins 0.000 claims abstract 9
- 239000000185 hemagglutinin Substances 0.000 claims abstract 9
- 101150013553 CD40 gene Proteins 0.000 claims abstract 8
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims abstract 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract 8
- 230000003308 immunostimulating effect Effects 0.000 claims abstract 7
- 102100028667 C-type lectin domain family 4 member A Human genes 0.000 claims abstract 6
- 101000766908 Homo sapiens C-type lectin domain family 4 member A Proteins 0.000 claims abstract 6
- 230000028993 immune response Effects 0.000 claims abstract 6
- 201000006082 Chickenpox Diseases 0.000 claims abstract 5
- 241000701022 Cytomegalovirus Species 0.000 claims abstract 5
- 102100034343 Integrase Human genes 0.000 claims abstract 5
- 241000712079 Measles morbillivirus Species 0.000 claims abstract 5
- 241001465754 Metazoa Species 0.000 claims abstract 5
- 108010006232 Neuraminidase Proteins 0.000 claims abstract 5
- 102000005348 Neuraminidase Human genes 0.000 claims abstract 5
- 101710192141 Protein Nef Proteins 0.000 claims abstract 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims abstract 5
- 241000711798 Rabies lyssavirus Species 0.000 claims abstract 5
- 241000702670 Rotavirus Species 0.000 claims abstract 5
- 241000193448 Ruminiclostridium thermocellum Species 0.000 claims abstract 5
- 206010046980 Varicella Diseases 0.000 claims abstract 5
- 108700004025 env Genes Proteins 0.000 claims abstract 5
- 108700004026 gag Genes Proteins 0.000 claims abstract 5
- 208000006454 hepatitis Diseases 0.000 claims abstract 5
- 231100000283 hepatitis Toxicity 0.000 claims abstract 5
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 claims abstract 5
- 108700004029 pol Genes Proteins 0.000 claims abstract 5
- 201000005404 rubella Diseases 0.000 claims abstract 5
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims abstract 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims abstract 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims abstract 4
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims abstract 4
- 102100028672 C-type lectin domain family 4 member D Human genes 0.000 claims abstract 4
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 claims abstract 4
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 claims abstract 4
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 claims abstract 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims abstract 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims abstract 4
- 102100032912 CD44 antigen Human genes 0.000 claims abstract 4
- 102100035793 CD83 antigen Human genes 0.000 claims abstract 4
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims abstract 4
- 206010069767 H1N1 influenza Diseases 0.000 claims abstract 4
- 208000009889 Herpes Simplex Diseases 0.000 claims abstract 4
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims abstract 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims abstract 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims abstract 4
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 claims abstract 4
- 101000766905 Homo sapiens C-type lectin domain family 4 member D Proteins 0.000 claims abstract 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims abstract 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims abstract 4
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims abstract 4
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims abstract 4
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims abstract 4
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims abstract 4
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims abstract 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims abstract 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims abstract 4
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims abstract 4
- 101001018258 Homo sapiens Macrophage receptor MARCO Proteins 0.000 claims abstract 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims abstract 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims abstract 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims abstract 4
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 claims abstract 4
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 claims abstract 4
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 claims abstract 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims abstract 4
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims abstract 4
- 108010073807 IgG Receptors Proteins 0.000 claims abstract 4
- 102000009490 IgG Receptors Human genes 0.000 claims abstract 4
- 102100022338 Integrin alpha-M Human genes 0.000 claims abstract 4
- 102100025304 Integrin beta-1 Human genes 0.000 claims abstract 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims abstract 4
- 102100037850 Interferon gamma Human genes 0.000 claims abstract 4
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims abstract 4
- 102100039564 Leukosialin Human genes 0.000 claims abstract 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims abstract 4
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims abstract 4
- 102000043129 MHC class I family Human genes 0.000 claims abstract 4
- 108091054437 MHC class I family Proteins 0.000 claims abstract 4
- 102000043131 MHC class II family Human genes 0.000 claims abstract 4
- 108091054438 MHC class II family Proteins 0.000 claims abstract 4
- 102100033272 Macrophage receptor MARCO Human genes 0.000 claims abstract 4
- 108010031099 Mannose Receptor Proteins 0.000 claims abstract 4
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims abstract 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims abstract 4
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 claims abstract 4
- 101710199789 Oxidized low-density lipoprotein receptor 1 Proteins 0.000 claims abstract 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims abstract 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract 4
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims abstract 4
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 claims abstract 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims abstract 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims abstract 4
- 108010025838 dectin 1 Proteins 0.000 claims abstract 4
- 206010022000 influenza Diseases 0.000 claims abstract 4
- 102000005962 receptors Human genes 0.000 claims abstract 4
- 108020003175 receptors Proteins 0.000 claims abstract 4
- 201000010740 swine influenza Diseases 0.000 claims abstract 4
- 241000710842 Japanese encephalitis virus Species 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims 35
- 210000004443 dendritic cell Anatomy 0.000 claims 26
- 201000001441 melanoma Diseases 0.000 claims 24
- 238000000034 method Methods 0.000 claims 17
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 16
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 15
- 102000002689 Toll-like receptor Human genes 0.000 claims 12
- 108020000411 Toll-like receptor Proteins 0.000 claims 12
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 8
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 claims 8
- 108010040721 Flagellin Proteins 0.000 claims 8
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 8
- 241000701806 Human papillomavirus Species 0.000 claims 8
- 108010063954 Mucins Proteins 0.000 claims 8
- 206010060862 Prostate cancer Diseases 0.000 claims 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 8
- 208000032839 leukemia Diseases 0.000 claims 8
- 239000000047 product Substances 0.000 claims 7
- 230000001580 bacterial effect Effects 0.000 claims 6
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 claims 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 108060000903 Beta-catenin Proteins 0.000 claims 4
- 102000015735 Beta-catenin Human genes 0.000 claims 4
- 208000018084 Bone neoplasm Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 108010060385 Cyclin B1 Proteins 0.000 claims 4
- 108090000259 Cyclin D Proteins 0.000 claims 4
- 102000003910 Cyclin D Human genes 0.000 claims 4
- 101150029707 ERBB2 gene Proteins 0.000 claims 4
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims 4
- 208000017604 Hodgkin disease Diseases 0.000 claims 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 4
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 108010008707 Mucin-1 Proteins 0.000 claims 4
- 102100034256 Mucin-1 Human genes 0.000 claims 4
- 102100034263 Mucin-2 Human genes 0.000 claims 4
- 108010008705 Mucin-2 Proteins 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 108060006580 PRAME Proteins 0.000 claims 4
- 102000036673 PRAME Human genes 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 208000002471 Penile Neoplasms Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 241001138501 Salmonella enterica Species 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 4
- 206010057644 Testis cancer Diseases 0.000 claims 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 4
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 4
- 102000003425 Tyrosinase Human genes 0.000 claims 4
- 108060008724 Tyrosinase Proteins 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 4
- 241000607626 Vibrio cholerae Species 0.000 claims 4
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims 4
- 210000000013 bile duct Anatomy 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 210000000621 bronchi Anatomy 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 210000003238 esophagus Anatomy 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 210000000232 gallbladder Anatomy 0.000 claims 4
- 150000002270 gangliosides Chemical class 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 210000000867 larynx Anatomy 0.000 claims 4
- 210000000088 lip Anatomy 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 238000012737 microarray-based gene expression Methods 0.000 claims 4
- 210000000214 mouth Anatomy 0.000 claims 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims 4
- 210000001989 nasopharynx Anatomy 0.000 claims 4
- 210000000653 nervous system Anatomy 0.000 claims 4
- 230000000926 neurological effect Effects 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 210000003800 pharynx Anatomy 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 210000002307 prostate Anatomy 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 230000002685 pulmonary effect Effects 0.000 claims 4
- 210000000664 rectum Anatomy 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 201000003120 testicular cancer Diseases 0.000 claims 4
- 201000002510 thyroid cancer Diseases 0.000 claims 4
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 4
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 210000003932 urinary bladder Anatomy 0.000 claims 4
- 206010046766 uterine cancer Diseases 0.000 claims 4
- 229940118696 vibrio cholerae Drugs 0.000 claims 4
- 241000712431 Influenza A virus Species 0.000 claims 3
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 claims 3
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 claims 3
- 206010014599 encephalitis Diseases 0.000 claims 3
- 208000020416 vascular bone neoplasm Diseases 0.000 claims 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims 2
- 241000588722 Escherichia Species 0.000 claims 2
- 241000186781 Listeria Species 0.000 claims 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 2
- 241000588653 Neisseria Species 0.000 claims 2
- 241000187654 Nocardia Species 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 241000607142 Salmonella Species 0.000 claims 2
- 241000191940 Staphylococcus Species 0.000 claims 2
- 241000194017 Streptococcus Species 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 230000003071 parasitic effect Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 206010046885 vaginal cancer Diseases 0.000 claims 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 201000011531 vascular cancer Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37376310P | 2010-08-13 | 2010-08-13 | |
| US61/373,763 | 2010-08-13 | ||
| PCT/US2011/047633 WO2012021834A1 (en) | 2010-08-13 | 2011-08-12 | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013110889A true RU2013110889A (ru) | 2014-09-20 |
Family
ID=45564978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013110889/10A RU2013110889A (ru) | 2010-08-13 | 2011-08-12 | Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120039916A1 (enExample) |
| EP (1) | EP2603235A4 (enExample) |
| JP (1) | JP2013535508A (enExample) |
| KR (1) | KR20130108295A (enExample) |
| CN (1) | CN103328005A (enExample) |
| AR (1) | AR082686A1 (enExample) |
| AU (1) | AU2011289234B2 (enExample) |
| BR (1) | BR112013002940A2 (enExample) |
| CA (1) | CA2807585A1 (enExample) |
| MX (1) | MX2013001527A (enExample) |
| RU (1) | RU2013110889A (enExample) |
| TW (1) | TWI506035B (enExample) |
| WO (1) | WO2012021834A1 (enExample) |
| ZA (1) | ZA201301013B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| CN101820910B (zh) * | 2007-05-03 | 2014-08-06 | 新加坡科技研究局 | 结合细胞内prl-1多肽或prl-3多肽的抗体 |
| TW201247706A (en) * | 2011-03-08 | 2012-12-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| US9045542B2 (en) | 2011-08-29 | 2015-06-02 | Baylor Research Institute | Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2) |
| EP2822599A4 (en) * | 2012-03-05 | 2015-12-23 | Univ Duke | VACCINE FORMULATION |
| CN103566377A (zh) * | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2014031984A1 (en) * | 2012-08-24 | 2014-02-27 | Baylor Research Institute | Immunological detection methods and compositions |
| CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
| EP3013362B1 (en) | 2013-06-28 | 2021-08-04 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| US10202450B2 (en) | 2013-09-05 | 2019-02-12 | Duke University | Nav 1.7 antibodies and methods of using the same |
| CA2936377A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating egfr expressing tumors |
| AU2015204503B2 (en) | 2014-01-13 | 2020-07-09 | Baylor Research Institute | Novel vaccines against HPV and HPV-related diseases |
| US20160340439A1 (en) * | 2014-01-22 | 2016-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy |
| CN106659774A (zh) | 2014-05-16 | 2017-05-10 | 贝勒研究院 | 用于治疗自身免疫和炎性病症的方法和组合物 |
| WO2015187637A1 (en) * | 2014-06-02 | 2015-12-10 | Baylor Research Institute | Methods and compositions for treating allergy and inflammatory diseases |
| US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| EP4001311B1 (en) | 2014-07-09 | 2025-11-05 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1/pd-1 combinations for treating tumors |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN104689313A (zh) * | 2015-03-04 | 2015-06-10 | 中国科学院海洋研究所 | 大菱鲆cd83分子作为疫苗佐剂的应用 |
| US10624964B2 (en) | 2015-05-01 | 2020-04-21 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CA3002095A1 (en) * | 2015-11-10 | 2017-05-18 | Yale University | Compositions and methods for treating autoimmune diseases and cancers |
| EP3389707B1 (en) | 2015-12-15 | 2025-08-20 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Immunogenic construct comprising an ebv-cell antigen and a targeting moiety and applications thereof |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN115554406A (zh) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| IL261188B (en) | 2016-03-04 | 2022-08-01 | Jn Biosciences Llc | An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues |
| IL263616B2 (en) | 2016-07-07 | 2025-01-01 | Univ Leland Stanford Junior | Antibody-adjuvant conjugates |
| WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CN108727503A (zh) * | 2017-04-18 | 2018-11-02 | 武汉博沃生物科技有限公司 | VZV重组gE-鞭毛素融合蛋白及其制备方法和应用 |
| CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CA3067268A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Crystalline resiquimod monosulfate anhydrate and its preparation and uses |
| WO2019006038A1 (en) * | 2017-06-28 | 2019-01-03 | The Board Of Trustees Of The Leland Stanford Junior University | METHODS AND COMPOSITIONS FOR STIMULATING DECTINE 2 AND CANCER IMMUNOTHERAPY |
| US20210369635A1 (en) * | 2017-11-29 | 2021-12-02 | Adaptive Phage Therapeutics, Inc. | Novel methods of vaccination using icosahedral phage |
| WO2019166432A1 (en) * | 2018-02-28 | 2019-09-06 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |
| US20220106566A1 (en) * | 2019-01-22 | 2022-04-07 | The Brigham And Women`S Hospital, Inc. | Antigen-Presenting Neutrophil-Derived Dendritic Cells and Methods of Use Thereof |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| WO2020193718A1 (en) | 2019-03-27 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| US20220298255A1 (en) * | 2019-05-31 | 2022-09-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | E-cadherin activating antibodies and uses thereof |
| CN114787181A (zh) * | 2019-11-21 | 2022-07-22 | Inserm(法国国家健康医学研究院) | 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| JP2023525140A (ja) | 2020-05-13 | 2023-06-14 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | Ｏｘ４０活性化特性を有する組換えタンパク質 |
| JP2023528017A (ja) | 2020-05-26 | 2023-07-03 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用 |
| CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
| CN111850006B (zh) * | 2020-07-27 | 2022-04-22 | 齐鲁工业大学 | 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36865及应用 |
| KR20230107260A (ko) | 2020-11-12 | 2023-07-14 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도 |
| US11572407B2 (en) * | 2020-11-18 | 2023-02-07 | Pionyr Immunotherapeutics, Inc. | Anti-MARCO antibodies and uses thereof |
| CA3205280A1 (en) | 2020-12-23 | 2022-06-30 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells |
| MX2023008986A (es) | 2021-01-29 | 2023-08-15 | Inst Nat Sante Rech Med | Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna. |
| CN118555970A (zh) * | 2021-11-04 | 2024-08-27 | 总医院有限公司 | 抗间皮素抗体试剂 |
| KR20240103030A (ko) | 2021-11-17 | 2024-07-03 | 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 | 범용 사르베코바이러스 백신 |
| WO2024074571A1 (en) | 2022-10-05 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Dc-targeting vaccine against nipah virus infection |
| EP4601682A1 (en) * | 2022-10-13 | 2025-08-20 | The Brigham & Women's Hospital, Inc. | Methods and compositions for improving response to immunotherapy |
| KR102878250B1 (ko) * | 2023-01-11 | 2025-10-31 | 서울대학교산학협력단 | 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물 |
| WO2024216189A1 (en) * | 2023-04-13 | 2024-10-17 | The Regents Of The University Of California | Isoform-independent antibodies to lipoprotein(a) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057915C (zh) * | 1994-09-19 | 2000-11-01 | 中国医学科学院医药生物技术研究所 | 免疫佐剂 |
| TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| EP2476432B1 (en) * | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| BRPI0807160A2 (pt) * | 2007-02-02 | 2018-09-25 | Baylor Res Institute | vacinas baseadas no direcionamento de antígeno ao dcir expresso em células apresentadoras de antígeno |
| TWI423985B (zh) * | 2007-02-23 | 2014-01-21 | Baylor Res Inst | 利用ｄｅｃｔｉｎ-１活化人類抗原呈現細胞之醫療應用 |
| BRPI0820270A2 (pt) * | 2007-11-07 | 2015-06-16 | Celldex Therapeutics Inc | Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular. |
| ES2685823T3 (es) * | 2008-07-16 | 2018-10-11 | Baylor Research Institute | Anticuerpos antagonistas anti-CD40 |
| JP2012520073A (ja) * | 2009-03-10 | 2012-09-06 | ベイラー リサーチ インスティテュート | 抗原提示細胞ターゲティングワクチン |
| CN105837691B (zh) * | 2009-03-10 | 2021-06-29 | 贝勒研究院 | 靶向抗原呈递细胞的癌症疫苗 |
| EP2406286B1 (en) * | 2009-03-10 | 2016-05-18 | Baylor Research Institute | Anti-cd40 antibodies and uses thereof |
| US20110274653A1 (en) * | 2010-05-07 | 2011-11-10 | Baylor Research Institute | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
-
2011
- 2011-08-12 TW TW100128970A patent/TWI506035B/zh not_active IP Right Cessation
- 2011-08-12 CA CA2807585A patent/CA2807585A1/en not_active Abandoned
- 2011-08-12 CN CN2011800489046A patent/CN103328005A/zh active Pending
- 2011-08-12 RU RU2013110889/10A patent/RU2013110889A/ru unknown
- 2011-08-12 BR BR112013002940A patent/BR112013002940A2/pt not_active IP Right Cessation
- 2011-08-12 KR KR1020137006354A patent/KR20130108295A/ko not_active Withdrawn
- 2011-08-12 JP JP2013524253A patent/JP2013535508A/ja active Pending
- 2011-08-12 MX MX2013001527A patent/MX2013001527A/es not_active Application Discontinuation
- 2011-08-12 EP EP11817128.9A patent/EP2603235A4/en not_active Withdrawn
- 2011-08-12 AR ARP110102955A patent/AR082686A1/es not_active Application Discontinuation
- 2011-08-12 US US13/208,993 patent/US20120039916A1/en not_active Abandoned
- 2011-08-12 AU AU2011289234A patent/AU2011289234B2/en not_active Ceased
- 2011-08-12 WO PCT/US2011/047633 patent/WO2012021834A1/en not_active Ceased
-
2013
- 2013-02-06 ZA ZA2013/01013A patent/ZA201301013B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2807585A1 (en) | 2012-02-16 |
| US20120039916A1 (en) | 2012-02-16 |
| JP2013535508A (ja) | 2013-09-12 |
| KR20130108295A (ko) | 2013-10-02 |
| BR112013002940A2 (pt) | 2019-09-24 |
| AR082686A1 (es) | 2012-12-26 |
| EP2603235A4 (en) | 2014-04-09 |
| EP2603235A1 (en) | 2013-06-19 |
| ZA201301013B (en) | 2015-10-28 |
| WO2012021834A1 (en) | 2012-02-16 |
| CN103328005A (zh) | 2013-09-25 |
| AU2011289234A1 (en) | 2013-02-21 |
| TWI506035B (zh) | 2015-11-01 |
| TW201208696A (en) | 2012-03-01 |
| AU2011289234B2 (en) | 2014-09-11 |
| MX2013001527A (es) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013110889A (ru) | Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки | |
| JP2013535508A5 (enExample) | ||
| US20120231023A1 (en) | Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells | |
| RU2012152828A (ru) | Опосредованное иммунорецепторами дендритных клеток (dcir) перекрестное примирование cd8+ т клеток человека | |
| Fukuyama et al. | Novel vaccine development strategies for inducing mucosal immunity | |
| US20120121592A1 (en) | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells | |
| WO2020191361A3 (en) | Extracellular vesicles for vaccine delivery | |
| Hesse et al. | In vivo targeting of human DC‐SIGN drastically enhances CD 8+ T‐cell‐mediated protective immunity | |
| TW201305193A (zh) | 靶向結核病（ｔｂ）疫苗之樹突細胞（ｄｃ） | |
| JP2015071598A5 (enExample) | ||
| CN103502439A (zh) | 用于抗原特异性t细胞增殖的方法 | |
| RU2012153053A (ru) | Вич вакцина, основанная на направленности максимизированных gag и nef на дендритные клетки | |
| Jia et al. | Immunogenicity of CTLA4 fusion anti-caries DNA vaccine in rabbits and monkeys | |
| JP2001524928A (ja) | クロスプライミング免疫による天然抗原に特異性を有するｃｔｌの誘導 | |
| Jemon et al. | An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy | |
| Petzold et al. | Targeted antigen delivery to DEC-205+ dendritic cells for tolerogenic vaccination | |
| Cohen et al. | CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens | |
| CN101426523B (zh) | 基于负载了天然杀伤t细胞的配体、和抗原的b细胞的疫苗 | |
| Silva et al. | Antigen delivery to DEC205+ dendritic cells induces immunological memory and protective therapeutic effects against HPV-associated tumors at different anatomical sites | |
| Prajeeth et al. | The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross‐priming against co‐administered and linked antigens | |
| Badillo-Godinez et al. | Induction of therapeutic protection in an HPV16-associated mouse tumor model through targeting the human papillomavirus-16 E5 protein to dendritic cells | |
| Yang et al. | Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant | |
| Park | Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivo | |
| Kitamura et al. | Long peptide vaccination can lead to lethality through CD4+ T cell-mediated cytokine storm | |
| WO2022049220A2 (en) | Antibody therapy |